Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Sponsor: Northwestern University
Terminated
Lack of funding, never moved into the phase II portion that was originally planned.
Other terminated trials from Northwestern University
Other Myelodysplastic Syndromes trials with similar outcome
Listed as NCT01009502, this PHASE1 trial focuses on Myelodysplastic Syndromes and remains terminated or withdrawn. Sponsored by Northwestern University, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Northwestern University
- Robert H. Lurie Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .